Caroline Ford

Associate Professor & Group Leader, Gynaecological Cancer Research Group

University of New South Wales - Randwick Campus

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Cancer Biology Cancer Biology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Caroline Ford is an Associate Professor and Group Leader of the Gynaecological Cancer Research Group at the University of New South Wales - Randwick Campus. Her research focuses on elucidating the complexities of endometriosis and ovarian cancer, as evidenced by her recent articles on the efficacy of novel therapeutic approaches and the use of cell-free DNA as a biomarker in clinical settings. Her work encompasses multi-kinase inhibitors, antibody-drug conjugates, and advanced computational models for cancer identification.

Articles (25)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (8)

Nikola A. Bowden

AUSTRALIA

View details

Maria Jose Garcia

Instituto de Investigaciones Biomédicas Alberto Sols

SPAIN

View details

Martin Widschwendter

University of Innsbruck

AUSTRIA

View details

K Warton

University of New South Wales

AUSTRALIA

View details

James D Brenton

UNITED KINGDOM

View details

Anais Alonso

UNSW Sydney

AUSTRALIA

View details

Peter Sinn

University Hospital

GERMANY

View details

Janusz Menkiszak

Head of the University Clinic

Pomeranian Medical University

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Caroline Ford

Research Interests

Explore related searches

Contact this professor

About

Articles (25)

Endometriosis is not the endometrium: Reviewing the over-representation of eutopic endometrium in endometriosis research

The Multi-Kinase Inhibitor GZD824 (Olverembatinib) Shows Pre-Clinical Efficacy in Endometrial Cancer

The antibody–drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models

Author Correction: A comparative analysis of 2D and 3D experimental data for the identification of the parameters of computational models (Scientific Reports, (2023), 13, 1, (15769), 10.1038/s41598-023-42486-3)

Cell‐free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer

Use of cell-free DNA from ascites to identify variants and tumour evolution in a cohort of patients with advanced ovarian cancer.

Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial

Abstract B014: Patient-derived organoid models for drug screening in molecular subtypes of endometrial cancer

Circulating cell-free DNA is elevated in postmenopausal compared with pre- and perimenopausal women

Circulating cell-free DNA is elevated in postmenopausal compared with pre- and perimenopausal women

Accurate Identification of Cancer Cells in Complex Pre-Clinical Models Using a Deep-Learning Neural Network: A Transfection-Free Approach

Beyond 2D cell cultures: how 3D models are changing the <i>in vitro</i> study of ovarian cancer and how to make the most of them

Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancer

Accurate Identification of Cancer Cells in Complex Pre‐Clinical Models Using a Deep‐Learning Neural Network: A Transfection‐Free Approach (Adv. Biology 11/2024)

Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response: A translational sub-study of the REZOLVE (ANZGOG-1101) clinical trial.

A comparative analysis of 2D and 3D experimental data for the identification of the parameters of computational models

Author Correction: ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target (Scientific Reports, (2020), 10, 1, (13906), 10.1038/s41598-020-70924-z)

Correction to: Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer (Oncogenesis, (2016), 5, 5, (e226), 10.1038/oncsis.2016.32)

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

Endogenous cell-free DNA in fetal bovine serum introduces artifacts to in vitro cell-free DNA models

Pan-Tissue and -Cancer Analysis of ROR1 and ROR2 Transcript Variants Identify Novel Functional Significance for an Alternative Splice Variant of ROR1

Circulating cell-free endometrial DNA level is unaltered during menstruation and in endometriosis

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival

Recovery Efficiency of Cell-Free DNA After Bisulfite Conversion

Circulating cell-free DNA undergoes significant decline in yield after prolonged storage time in both plasma and purified form.

Collaborators (8)

Nikola A. Bowden

Maria Jose Garcia

Martin Widschwendter

K Warton

James D Brenton

Anais Alonso

Peter Sinn

Janusz Menkiszak

Make your next move.